Clinical Trials
37
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)• Click on a phase to view related trials
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
- Conditions
- Chronic Heart Failure
- Interventions
- Drug: JTT-861 CapsulesDrug: Placebo Capsules
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06017609
- Locations
- 🇺🇸
Nature Coast Clinical Research, Crystal River, Florida, United States
🇺🇸Indago Research & Health Center, Inc., Hialeah, Florida, United States
🇺🇸Pharma Medical Innovation, Inc., Miami Lakes, Florida, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT04465877
- Locations
- 🇺🇸
Qps-Mra, Llc, Miami, Florida, United States
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- PsoriasisSkin DiseasesPlaque Psoriasis
- Interventions
- Drug: JTE-451 TabletsDrug: Placebo Tablets
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT03832738
- Locations
- 🇺🇸
Clinical Science Institute, Santa Monica, California, United States
🇺🇸Advanced Dermatology and Skin Cancer Specialists, Temecula, California, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Akros Pharma Inc.
- Registration Number
- NCT03789643
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03358290
- Locations
- 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸Center For Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸University of South Florida - Hospital, Tampa, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Shionogi to Acquire Japan Tobacco's Pharmaceutical Subsidiaries for $1.1 Billion
Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.